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One major limitation of UCBT is the lack of donor cells available for posttransplantation donor leukocyte
infusions (DLI) to boost immunity or induce graft-versus-leukemia (GVL) activity. Starting from a 5% frac-
tion of a UCB graft, we report the feasibility and biological characteristics of ex vivo expansion of frozen/
thawed CB T cells by anti-CD3 and anti-CD28 antibody–coated Dynal beads in the presence of interleukin
(IL)-2. We postulated that while undergoing expansion, UCB T cells may mature toward a Th1/Tc1 pheno-
type and acquire the potential for cytotoxicity. Whereas an almost 2-log expansion also led to the acquisition
of IL-12Ra and an increase in Th1 characteristics, postexpansion lymphocytes produced less interferon-g,
tumor necrosis factor-a, and granzyme B; stored almost no perforin; and lacked cytotoxicity against alloge-
neic targets. Collectively, these suggest relative safety from acute/hyperacute graft-versus-host disease.
CD81 T cells expanded preferentially, whereas a higher rate of apoptosis in CD41 T cells also promoted
an inverted CD4/CD8 ratio. Most expanded T cells retained expression of CD27, CD28, and L-selectin
but down-regulated CCR-7. In summary, UCB T cell proliferation sustained by CD3/CD28 co-stimulatory
beads and IL-2 can lead to clinically relevant doses of DLI from a very small fraction of the UCB graft, although
future strategies to reduce apoptosis may enhance their clinical potential.
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Unrelated umbilical cord blood transplantation
(UCBT) is a life-saving form of hematopoietic cell
transplantation (HCT) for patients who lack HLA-
matched sibling or living unrelated donors. But the
use of UCBT is limited by a high incidence of oppor-
tunistic infections (OIs) within the first 100 days post-
transplantation, most of which are viral. OI, caused by
delays in immune reconstitution, is the major cause of
death during the first 6 months after transplantation
[1]. Protective antiviral immunity resides primarily in
the T cell compartment of the adaptive immune sys-
tem. For several months post-UCBT, until recovery
of the thymus is restored to support de novo T cell
generation, protective antiviral immunity depends on
the activity of postthymic T cells that are infused
within the cord blood (CB) grafts. But CB T cells are
antigen-inexperienced (ie, naı¨ve) lymphocytes that
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1190have been biased in utero by anti-inflammatory
placental factors that are Th2 trophic and/or Th1 sup-
pressive (eg, interleukin [IL]-4, IL-10, transforming
growth factor-b, prostaglandin E2 [2]), which together
protect pregnancy [3]. CB T cells have been called
‘‘immature’’ because of their impaired capacity for
Th1/Tc1 cytokine production [4] and diminished
cytolytic activity [5] compared with adult T cells [6].
The relative cytolytic deficiency of CB T cells is
associated with absent expression of granzymes and
perforin [7], which are essential for eradicating viral
pathogens. The exuberant production of the Th2 cyto-
kine IL-13 by CD81CBT cells [8] is paired with poor
interferon (IFN)-g production by CD41CBT cells as
a consequence of hypermethylation of the IFN-g pro-
moter [2, 9]. Not surprisingly, CB T cells infused into
transplant recipients need to undergo in vivo priming,
maturation, and peripheral expansion before they can
afford immunologic protection. By analyzing the
reconstitution of the T cell and dendritic cell compart-
ment within the first 50 days after UCBT, we previ-
ously demonstrated that lower doses of infused T
cells/kg and lower absolute numbers of CD41 T cells
in the circulation are independently associated with
an increased risk for OIs and OI-related mortality [1].
Bulk donor leukocyte infusions (DLIs) that contain
antigen-specific memory cells have proved efficacious
in the post–bone marrow transplantation (BMT) set-
ting to control and eradicate Epstein Barr virus
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[10,11]. There is no obvious available source for adop-
tive cell therapy strategies in the UCBT setting, how-
ever. Ex vivo T cell expansion from a small fraction of
a hematopoietic cell graft would be an ideal approach
to generate T cells for the purpose of DLI. In vitro T
cell expansion has been attained by various methods,
but it gained particular clinical relevance once artificial
antigen-presenting cells (APCs) became available. The
clinical applicability of anti-CD3 plus anti-CD28 stim-
ulatory antibody-coated paramagnetic Dynal M-450
tosylactivated beads has been amply demonstrated [12-
15]. These artificial APC beads provide simultaneous
T cell receptor (TCR) agonist and costimulating signals
to trigger T cell activation and eventual blastogenesis
[16]. Recently, CD3/CD28 beads were shown to be ca-
pable of expanding CB T cells by up to 2 log over the
course of 12 to17days [17]. Bead-selected and expanded
CB T cells expressed an almost even mixture of naı¨ve,
central memory, and effector memory phenotype and
retained the preexpansion polyclonal TCR diversity,
similar to the effects of expanding adult T cells [17].
In the present study, we evaluated the feasibility
and biological consequences of ex vivo expansion of
frozen/thawed CB T cells on anti-CD3 plus anti-
CD28 antibody-coated Dynal beads in the presence
of IL-2 from a small (5%) fraction of the CB graft.
We hypothesized that removing such a small aliquot
would not impair the engraftment potential of the in-
fused 95% fraction, and that successful expansion from
the 5% fraction could generate a clinically relevant cel-
lular product. We also postulated that while undergo-
ing expansion, CB T cells also may mature toward
a Th1/Tc1 phenotype and thereby acquire the poten-
tial to function as a cytotoxic effector, as demonstrated
by the expression of essential cytokines and de novo ex-
pression of the granzyme-perforin pathway. Here we
confirm the expansion potential of CB T cells and re-
port that during expansion, these cells undergo partial
maturation toward a Th1 phenotype, although this is
offset by preferential apoptosis among CD41 T cells.
METHODS
Specimens
Collected CB samples were obtained from frozen re-
search units processed at the Duke University Stem Cell
Laboratory and the Carolinas Cord Blood Bank at Duke
University. These anonymous specimens were not eligi-
ble for clinical use because of insufficient volume.
T Cell Enrichment and Expansion System
TheCB samples, with a leukocyte content\5%of
that of an average CB graft, were thawed in 5% human
albumin and 10% dextran 40 in 0.9% sodium chloridesolution and rested for 1 hour. Mononuclear cells
(MNCs) were obtained by density gradient centrifuga-
tion over Ficoll (Pharmacia Fine Chemicals, Uppsala,
Sweden) and washed. CD31 T cells were enriched by
negative immunomagnetic selection using the EasySep
T Cell Enrichment Cocktail (StemCell Technology),
depleting CD141, CD161, CD191, CD561, and
glycophorin A1 cells following the manufacturer’s
instructions. Fluorescent activated cell sorter (FACS)
analysis determined the purity of the negatively
selected T cells to be 75% to 90%. Expansion was
started at a density of 6 to 8  105 T cells/mL in
gas-permeable VueLife Teflon bags (American Fluo-
roseal, Gaithesburg, MD). T cells were incubated
with CD3/28 T Cell Expander artificial antigen-pre-
senting cell beads (Dynal/Invitrogen, Sammamish,
WA) at a ratio of 3:1 in X Vivo-15 (BioWhittacker,
Walkersville, MD) plus 5.5 1025 M beta mercaptoe-
thanol, 10 mMHEPES, 200u/mL of IL-2 (Proleukin;
Novartis, East Hanover, NJ), and 5% heat-inactivated
pooled human AB serum (NABI, Miami, FL). The
starting absolute T cell numbers were 1 to 2  106
CD31 T cells. Medium and cytokines were replen-
ished 3 times per week to maintain a concentration
of  1  106 cells/mL based on nucleated cell count,
obtained by an automated hematology analyzer (Sys-
mex K-1000; GMI, Ramsey, MN). After 12 to 14
days, the cells were harvested and washed, and the
beads were removed using a magnetic particle concen-
trator (Dynal MPC-2; Dynal/Invitrogen). T cells were
assessed for viability manually by Trypan blue staining
along with flow cytometric characterization to evaluate
proliferation, apoptosis, changes affecting their surface
and intracellular phenotype, homing receptors, and
cytokine secretion.
Immunophenotypic Characterization of the
Expanded T Cells
Surface and intracellular T cell immunophenotyp-
ing and T cell enumeration was performed by 4-color
FACS staining as described previously [18,19,29]. One
fluorescent channel (FL-3) was dedicated to gate only
on CD31 T cells, whereas the FL-4 channel was ded-
icated to identifying subsets based on either CD4 or
CD8 staining. Acquisition was performed with
a FACSCalibur flow cytometer (BD Biosciences); typ-
ically, . 5000 CD31 events in FL-3 were acquired to
perform a subset analysis. Lymphocyte subset–
specific surface markers were monitored in the FL-1
and FL-2 fluorescent channels to analyze antigen ex-
pression over isotype controls, whereas intracellular
cytokine production was monitored in FL-1, FL-2,
and FL-4 channels. All antibodies, including isotype-
specific negative controls, were purchased from BD
Biosciences, except anti–granzyme B, purchased from
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from R&D Systems (Minneapolis, MN)
Statistical Analysis
Two-tailed t-tests were used for statistical compar-
isons between test and control conditions. Statistical
significance was set at P\ .05.
RESULTS
Differential T Cell Expansion and Apoptosis
among CD41 and CD81 Cells
Onemajor limitation of UCBT is the lack of donor
cells available for posttransplantation DLI to boost
immunity or induce GVL activity. We evaluated the
feasibility of T cell expansion from thawed CB and an-
alyzed the biological effects of T cell proliferation
stimulated by CD3/CD28 costimulatory beads plus
IL-2 in clinical-grade gas-permeable bags. At the end
of 14 days, the ex vivo cultured CB T cells had ex-
panded 76-fold (6 42-fold; n 5 10), with up to 40%
of T cells in the cell cycle as measured by ic Ki-67
expression (Figure 1; Table 1). Expansion was inferior
if starting cultures were impure, due at least in part to
phagocytosis of the beads by monocytes/macrophages
(data not shown). A significant evolution in phenotype
was noted after 2 weeks in culture (Figure 1; Table 1).
Of note, expansion on CD3/28 APC beads in the pres-
ence of IL-2 led to inversion of the CD4/CD8 ratio,with a median frequency of 40% CD41 T cells at
day 14, compared with 74% at day 0 [18]. This relative
CD81 dominance likely can be attributed to two
parallel processes. At the end of expansion, 46% of
the CD81T cells were still in the cell cycle, in contrast
with 37% of CD41 T cells (median values), as
determined based on ic expression of Ki-67 (P 5 .05)
(Table 1). The expansion advantage of CD81 T cells
was accompanied by a significantly higher rate of apo-
ptosis among CD41 T cells (P5 .002), as determined
based on the intracellular expression of activated
caspase 3 (Table 1; Figure 2). It is important to note
that apoptosis was scored in T cells that otherwise
were considered viable based on their surface CD3
expression and ‘‘healthy’’ forward- and side-scatter
flow cytometry characteristics.
To better assess cell death, we also monitored the
fraction of viable CD31 cells among all CD451 cellu-
lar events detectable by 4-color flow cytometry. Ac-
cording to this FACS criterion, at the end of
expansion, viable CD31 cells represented 54% 6
16% of all CD451 cellular events. This stands in con-
trast to the findings of the assessment by Trypan blue
staining, in which viability typically remained . 85%,
data not shown.Monitoring by flow cytometry, a more
sensitive and objective tool, can demonstrate that over
the course of expansion, ongoing apoptosis at a rate of
15% (Table 1) provided a constant influx of T cells
into the nonviable fraction. Termination of expansion
cultures at an earlier time point (eg, on days 10-12Figure 1. Phenotypic evolution, proliferation and apoptosis in the expanded T cell progeny. A 4-color FACS dotplot profile of viable T lymphocytes
contrasting the starting day 0 and post-expansion day 14 progeny. Surface detection of indicated antibodies is presented except for Ki-67 and activated
caspase-3, which were detected following permeabilization and intracellular staining. The relative size of the indicated T cell subsets in a quadrant is
expressed as the percentage of total viable T cells. Representative experiment, n 5 10.
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expansion. Similarly, extending cultures beyond day
14 up to day 18 in the hope that ongoing proliferation
could still override apoptosis also yielded inferior
expansion results compared with those for days 12 to
14 (data not shown).
Proliferation Induced by CD3/CD28
Costimulatory Beads Results in an Activated
Surface Phenotype and aMorePronouncedTh1/
Tc1 Profile
Compared with the starting population of ‘‘rest-
ing’’ CB T cells [18], most of the expanded cells
acquired the surface phenotype of activated
(ie, HLA-DR1/CD45RO1 and CD251 T cells)
‘‘memory-like’’ cells, at the expense of naive/recent
thymic emigrants that coexpress CD45RA and
CD62L. Notably, after 12 to 14 days of expansion,
most T cells coexpressed CD45RA and CD45RO,
similar to what occurred previously within a few days
after stimulation with phytohemagglutinin [20-22].
Despite the proliferation-induced evolution of immu-
nophenotype,. 90% of the expanded T cells retained
expression of CD62L. Similarly, CD27 and CD28 ex-
Table 1. Maturational changes of CD3/CD28 bead-expanded
CB T cells (n 5 10)
Variable Mean SD
% CD3+ 99 3
% CD4+ 39 9
% CD28+/CD3+ 96 7
% CD27+/CD3+ 98 1
% CD45RA+/RO- 16 14
% CD45RA-/RO+ 39 26
% CD25+/CD3+ 57 19
% CD25+/CD4+ 85 10
% CD45RA+/CD62L+ 58 23
% CD62L+/CD3+ 92 6
% CCR7+/CD3+ 32 14
% CD212+/CD3+ 49 22
% CD45RA+/CD27+/CD8+ (naı¨ve CD8+) 73 14
% CD45RA-/CD27+/CD8+ (central memory
CD8+)
24 14
% CD45RA+/CD27-/CD8+ (RA + Effector Memory) 2 1
% CD57+/CD28-/CD8+ (effector CTLs) 0 0
% Ki67+/CD8+ 39 14
% KI-67+/CD4+ 35 12
% HLA-DR+/CD3+ 41 16
% HLA-DR+/CD4+ 36 18
% HLA-DR+/CD8+ 51 18
% Granzyme A+/CD8+ 53 17
% Granzyme B+/CD8+ 9 5
% Perforin+/CD8+ 2 1
% INF-g+/CD3+ 4 5
% TNF-a+/CD3+ 27 24
% IL2+/CD4+ 21 12
% IL4+/CD3+ 0 0
% Activated
caspase 3+/CD4+
16 9
% Activated
caspase 3+/CD8+
13 10
Four-color surface and intracellular FACS immunophenotype of
lymphocytes after 14 days of culture by anti-CD3 plus anti-CD28
antibody–coated Dynal beads in the presence of IL-2.pression was present in . 97% of CD31 T cells post-
expansion. Although the maintenance of L-selectin
expression (ie, CD62L) suggests a preserved capability
to migrate to secondary peripheral lymphoid organs
for antigenic encounters, CCR7 expression remained
detectable on only a 1/3 of the expanded progeny
(Table 1). This could result in diminished lymph
node retention if expanded cells were adoptively trans-
ferred. Tissue homing molecules, which are notably
absent on the surface of fresh unmanipulated CB
[18], were expressed to varying degrees, with ‘‘skin
homing’’ CCR4 and CLA detectable on 5% to
15% of CD31 cells and the presumably ‘‘gut homing’’
CCR-9 remaining mostly undetectable (data not
shown).
Significant Th1/Tc1 cell maturation after expan-
sion was observed. After expansion, T cells acquired
the capacity to secrete IFN-g, (Figure 2), compared
with minimal (if any) secretion by fresh uncultured
CB T cells. Similarly, . 50% of the T cells expressed
IL-12Ra (CD212) at a median 56% postexpansion
(Table 1). IL-2 and tumor necrosis factor (TNF)-a se-
cretion also were enhanced (Table 1); most of the
TNF-a–secreting T cells were simultaneously secret-
ing IL-2 as well (data not shown). Despite these matu-
rational events, a much larger fraction of unstimulated
adult peripheral blood T cells is capable of secreting
these cytokines, as has been demonstrated by others
[4] and us (data not shown), suggesting only partial
maturation along the Th1/Tc1 direction in the postex-
pansion CB T cells.
Low Expression of Perforin and Granzyme B
Correspond with the Absence of Effector CTL
Population and Lack of Cytotoxicity
Postexpansion
Because fresh CBT cells have virtually no cytotox-
icity [6], coinciding with the absence of intracellularly
stored granzymes A and B and perforin, after expan-
sion, we evaluated for the de novo expression of these
critical mediators of cytotoxicity. Whereas granzyme
A was stored in many postexpansion CD81 T cells
(Figure 2; Table 1), intracellular granzyme B expres-
sion was detected at significantly lower frequency
(9% 6 5%) than in normal adult peripheral blood
[23] (35% 6 15% in our laboratory; P\ .001; data
not shown). Moreover, preformed intracellular per-
forin was detected in very few CD81 T cells (Table
1), which correlates with the paucity of CD571/
CD28-/CD81 effector CTL cells (Table 1). Taken
together, these findings may explain the complete
absence of cytotoxicity postexpansion, even at a high
effector-to-target ratio (60:1), against a highly immu-
nogenic EBV1 (and HLA-DR1, CD401, CD801,
and CD861) allogeneic lymphoma cell line (IM9) de-
spite a week of prestimulation that caused adult blood
1194 Biol Blood Marrow Transplant 14:1190-1196, 2008M. A. Mazur et al.Figure 2. Th1/Tc1 cytokine secretion profile and Granzyme A expression in the expanded T cell progeny. A 4-color FACS dotplot profile of viable T
lymphocytes contrasting the starting day 0 and postexpansion day 14 progeny. Surface detection of indicated antibodies is presented except for IL-2,
TNFa, and Granzyme B, which were detected following permeabilization and intracellular staining. The relative size of the indicated T cell subsets in
a quadrant is expressed as the percentage of total viable T cells. Representative experiment, n 510.T cells to attain a specific killing rate . 50% to 60%
(data not shown). Nevertheless, the expanded T cell
progeny contained significantly more of these cytotox-
icity effectors compared with the preexpansion resting
T cells.
DISCUSSION
Our experiments demonstrated significant T cell
expansion matched with partial maturation among
the proliferating CB T cells. The expansion of viable
CB T cells has now reached clinically relevant num-
bers. For example, starting with 2  106 total CB T
cells derived from\ 3% of a typical thawed CB graft,
if this were expanded by 70-fold, the progeny could
provide a DLI product with up to 2  106 T cells/kg
for patients weighing # 60 kg. Although in our cul-
tures, different clones of anti-CD3 and anti-CD28
monoclonal antibodies were linked to the Dynal beads
compared with those linked to the Xcyte beads used by
Parmar et al. [17], we can corroborate that up to 100-
fold expansion can be attained. Our expansion may be
spuriously lower, however, because we enumerated
viable CD31 T cells using Trucount FACS-based
technology; nonetheless, the total nucleated cell count
was invariably higher, typically by 10% to 30%.
Others, focusing on expanding CD251 regulatory T
cells from CB, also demonstrated expansion of nonre-
gulatory T cells [24,25], although they did not perform
similar phenotypic and functional characterization of
these cells.
Our findings reveal significant immunophenotypic
evolution among the expanded cells both on thesurface and intracellularly. These changes could have
possible clinical relevance if cells expanded by this
method were infused as DLI products. In contrast
with Parmar et al. [17], we found significantly less
(\ 3%) ‘‘terminally differentiated’’ CD81 T cells
(CD27-/CD28-), and the newly emerging ‘‘central
memory’’ subset (CD45RA-/CD271) represents \
33% of the progeny in our cultures, possibly reflecting
different CD3/CD28 stimulatory beads and different
levels of activation. The absence of effector CTLs is
not surprising, considering that during expansion,
CD81 T cells in our cultures do not receive a ‘‘third
signal’’ in the form of IL-12, Toll-like receptor
ligands, or type I IFNs [26]. Most of the expanded cells
in our culture retained several surface markers of the
starting pool of ‘‘naı¨ve/resting’’ T cells, with . 90%
of the expanded progeny expressing CD62L, CD27,
and CD28; however, there is ample evidence that
significant activation occurred in these cultures, based
on the high expression of HLA-DR and CD25 and the
acquisition of CD212 (Table 1). Moreover, TNF-a,
IL-2, and IFN-g–secreting cells were more prevalent
compared with in the starting cultures, and the gran-
zyme A–expressing CD81 T cell pool was remarkably
reconstituted, similar to what can be seen in normal
adult peripheral blood, as illustrated in Figure 2. How-
ever, compared with resting adult peripheral blood,
fewer CD81 T cells stored granzyme B, and no
CD571/perforin1 cells were detected in any of our
experiments. These findings may explain the complete
absence of cytotoxicity against a highly immunogenic
allogeneic target.
Although this apparent lack of cytotoxicity against
an HLA-mismatched cell line suggests relative safety
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ings emerge from the extensive analysis of the
expanded T cells when taken to the clinical arena.
Whereas Parmar et al. [17] found no change in TCR
diversity, the inversion of CD4/CD8 ratio seen in
our cultures reflects a different degree of proliferation,
along with a significant degree of apoptosis that can
vary among specific T cell subsets. These characteris-
tics together may result in the survival of only a select
fraction of the expanded cells. Apoptosis could be even
greater once these cells were infused, because the level
of endogenous IL-2 would likely be  2 log less than
that in the ex vivo cytokine-supplemented cultures.
The possibility of accelerated apoptosis through
‘‘death by neglect’’ may not be as clinically relevant
in most of the clinical settings evaluated to date. Clin-
ical trials with CD3/28-expanded DLI products have
reported long-term T cell survival and even significant
lymphocytosis [13,15,27]; moreover, autologous DLI
even corrected skewed TCR diversity [14]. But almost
all of the adoptive T cell infusions were performed in
the autologous setting, and DLI doses in the 107/kg
to 108/kg range typically were infused. These doses
may be 10-fold to 50-fold greater than what can be
provided in the UCBT setting. Moreover, immuno-
suppressive drugs, which are essential in the HLA-
mismatched UCBT setting to prevent GVHD, cer-
tainly will pose an additional barrier. A lower DLI
cell dose together with immunosuppressive drugs in
the circulation could hamper clinically relevant
changes in T cell reconstitution if significant apoptosis
is already occurring in vitro. Evidence supporting this
concern comes from studies that compared adult lym-
phocytes with CB T cells and found that the latter are
more likely to undergo activation-induced cell death
after strong TCR signaling, such as allopriming [28].
Although we have demonstrated a robust expansion
potential from a very small starting fraction associated
with partial Th1/Tc1 maturation, clearly another
important finding of our study is the significant rate
of apoptosis, particularly among CD41T cells, result-
ing in an inverted CD4/CD8 ratio. In contrast, the
phenotypic evolution of the naı¨ve T cell population to-
ward a central memory phenotype is of less concern,
because these cells remain antigen-inexperienced,
and their future priming in DLI recipients in vivo
will require their homing and retention in secondary
lymphoid tissues. Retention may be compromised,
however, due to the progressive loss of CCR7 observed
after 14 days in culture.
In summary, although the clinical implications of
our study are very encouraging, as are those of Parmar
et al. from the M.D. Anderson Cancer Center [17], we
believe that at least 3 areas merit further study and pos-
sible modifications to improve on these encouraging
preclinical findings: (1) reducing apoptosis among
IL-2 and bead-activated T cells, particularly inCD41 T cells; (2) increasing the rate of expansion to
reach potentially higher DLI dose levels, allowing
adults of all sizes to benefit fromDLI; and (3) inducing
some additional functional maturation toward Th1/
Tc1 competence while retaining low/minimal alloge-
neic cytotoxicity and sufficiently high expression of
homing molecules necessary for entry and retention
in secondary lymphoid organs. Once these conditions
are satisfied, DLI may not only be safe for use in the
UCBT setting, but also ex vivo expandedT cells would
have the potential for more effective control and/or
reduction of the opportunistic viral infections so com-
mon after UCBT [1]. It is also noteworthy that after
DLI infusion, the expanded cells may undergo further
functionial maturation in vivo and may attain GVL
activity as well. Nonetheless, we believe that some
degree of ‘‘immaturity’’ should be retained in the
expanded CB T cells before DLI infusion, as opposed
to full adult-like cytotoxicity, which could lead to
severe alloreactivity/GVHD in the unrelated HLA-
mismatched setting. It is essential that engineered
DLI products generated from CB retain the ability
to safely cross the HLA barrier as one of the most
significant benefits of UCBT.
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